Host country for firms selling cancer drugs as a monopoly
Today Paul Miano published this report: Cancer: Approval, ownership, market structure, and placement on WHO Model Essential Medicines List, for 100 new molecular entities (NMEs) on the NCI alpha list of cancer drugs and vaccines, KEI Research Note 2011:1.
One of the findings of the report: ownership of cancer drugs sold as a monopoly is concentrated in six countries. And, 85 percent of patented cancer drugs are owned by firms from the US, the UK and Switzerland.
